Related Experiment Video
Updated: Jul 19, 2026

Murine Mesenteric Lymphadenectomy for Selective Disruption of Lymphatic Communication with Region-Specific Gut
Published on: December 30, 2025
Normal mesenteric lymph blunts the pulmonary inflammatory response to endotoxin
Aaron M Cheng1, Ernest E Moore, Tomohiko Masuno
1Department of Surgery, Denver Health Medical Center, University of Colorado Health Sciences Center, Denver, Colorado 80204, USA.
Background:
Mesenteric lymph may provide the mechanistic link between gut ischemia and acute lung injury after hemorrhagic shock (HS). Studies have focused on the toxic mediators that develop in the post-shock mesenteric lymph (PSML). However, a complementary possibility is that there is loss of protective mediators found in pre-shock normal mesenteric lymph (NML) after HS. We hypothesize that NML protects against inflammatory insults to the pulmonary endothelium and that this effect is lost in PSML.
Materials And Methods:
Primary human pulmonary endothelial cells (HMVECs) were incubated with NML or PSML collected from rats subjected to HS and resuscitation and then stimulated with 20 ng/mL LPS. ICAM-1 surface expression was measured by flow cytometry. In subsequent experiments, lipoproteins were extracted from NML before incubation and LPS-induced ICAM-1 expression determined.
Results:
Mean fluorescent intensity (MFI) of LPS-induced ICAM-1 in NML and PSML treated HMVECs were 10.1 +/- 2.3 versus 27.7 +/- 0.83, respectively (P < 0.05). This represented at 71% decrease in ICAM-1 expression by NML compared to ICAM-1 expression in LPS-induced controls (MFI: 34.6 +/- 6.9). Lipoprotein extraction from NML abolished this protective effect (MFI: 31.2 +/- 5.3 versus Control + LPS: 33.5 +/- 3.6, P > 0.05). Baseline ICAM-1 levels were not significantly different among control, NML, and PSML groups.
Conclusion:
Lipoproteins in NML contain anti-inflammatory properties that decrease ICAM-1 expression induced by LPS in pulmonary endothelium. Decreased protective lipoproteins after HS and resuscitation may contribute to the toxicity associated with PSML from the ischemic gut.
Insights
Normal mesenteric lymph (NML) protects against lung inflammation by decreasing ICAM-1 expression. This protective effect is lost in post-shock mesenteric lymph (PSML) due to decreased lipoproteins after hemorrhagic shock.
Area of Science:
- Endocrinology
- Immunology
- Pathophysiology
Background:
- Hemorrhagic shock (HS) can lead to acute lung injury (ALI).
- Mesenteric lymph is a potential mediator linking gut ischemia and ALI post-HS.
- Focus has been on toxic mediators in post-shock mesenteric lymph (PSML), but loss of protective mediators in normal mesenteric lymph (NML) is also possible.
Purpose of the Study:
- To investigate the protective role of NML against inflammatory insults to pulmonary endothelium.
- To determine if this protective effect is diminished in PSML.
- To identify the components within NML responsible for this protective effect.
Main Methods:
- Primary human pulmonary endothelial cells (HMVECs) were incubated with NML or PSML from rats subjected to HS and resuscitation.
- Cells were stimulated with lipopolysaccharide (LPS) to induce inflammation.
- ICAM-1 surface expression was measured by flow cytometry.
- Lipoproteins were extracted from NML to assess their role in the protective effect.
Main Results:
- NML significantly decreased LPS-induced ICAM-1 expression on HMVECs by 71% compared to controls.
- PSML did not show this protective effect, with significantly higher ICAM-1 expression than NML.
- Extraction of lipoproteins from NML abolished its protective effect against LPS-induced ICAM-1 expression.
Conclusions:
- Lipoproteins in NML possess anti-inflammatory properties that reduce LPS-induced ICAM-1 expression in pulmonary endothelium.
- A reduction in these protective lipoproteins in mesenteric lymph following HS and resuscitation may contribute to PSML-induced lung injury.
Related Concept Videos
Inflammatory Bowel Disease III: Crohn's Disease
Chronic Inflammation: Introduction
Inflammatory Bowel Disease II: Ulcerative Colitis
